key: cord-0917981-x7qx36mo authors: Malagón, Talía; Yong, Jean H. E.; Tope, Parker; Miller, Wilson H.; Franco, Eduardo L. title: Predicted long‐term impact of COVID‐19 pandemic‐related care delays on cancer mortality in Canada date: 2021-12-03 journal: Int J Cancer DOI: 10.1002/ijc.33884 sha: 717763cab08de09c22a4a21ebbfad6ea36a7d3cc doc_id: 917981 cord_uid: x7qx36mo The COVID‐19 pandemic has affected cancer care worldwide. This study aimed to estimate the long‐term impacts of cancer care disruptions on cancer mortality in Canada using a microsimulation model. The model simulates cancer incidence and survival using cancer incidence, stage at diagnosis and survival data from the Canadian Cancer Registry. We modeled reported declines in cancer diagnoses and treatments recorded in provincial administrative datasets in March 2020 to June 2021. Based on the literature, we assumed that diagnostic and treatment delays lead to a 6% higher rate of cancer death per 4‐week delay. After June 2021, we assessed scenarios where cancer treatment capacity returned to prepandemic levels, or to 10% higher or lower than prepandemic levels. Results are the median predictions of 10 stochastic simulations. The model predicts that cancer care disruptions during the COVID‐19 pandemic could lead to 21 247 (2.0%) more cancer deaths in Canada in 2020 to 2030, assuming treatment capacity is recovered to 2019 prepandemic levels in 2021. This represents 355 172 life years lost expected due to pandemic‐related diagnostic and treatment delays. The largest number of expected excess cancer deaths was predicted for breast, lung and colorectal cancers, and in the provinces of Ontario, Québec and British Columbia. Diagnostic and treatment capacity in 2021 onward highly influenced the number of cancer deaths over the next decade. Cancer care disruptions during the COVID‐19 pandemic could lead to significant life loss; however, most of these could be mitigated by increasing diagnostic and treatment capacity in the short‐term to address the service backlog. created a model to predict the effect of these disruptions on long-term cancer mortality. The model predicted a 2% increase in cancer deaths over the next 10 years. However, they also show that by increasing the capacity of cancer care services by at least 10% to tackle the backlog, most excess deaths could be avoided. The coronavirus disease 2019 (COVID- 19) pandemic has led to severe disruptions in healthcare delivery worldwide. Cancer patients are at particularly high risk of negative outcomes from delays in diagnosis and treatment. A meta-analysis estimated that each 4-week delay in cancer surgery increases the rate of mortality by 6% to 8% across several major cancer sites. 1 The pandemic has impacted the entire cancer care trajectory due to changes in healthcare seeking behavior and health system capacity. 2 Many individuals have delayed consulting for cancer-related symptoms due to access barriers, or fears of infection with coronavirus in a healthcare setting. 3, 4 Healthcare staffing shortages may occur due to redeployment to the pandemic response, leave due to coronavirus infection, burnout or increased childcare responsibilities. Key cancer diagnostic tests, such as endoscopies, colonoscopies, mammographies, computerized tomography (CT) scans and magnetic resonance imaging (MRI) scans, have declined, 5,6 either due to fewer patient referrals or delays in accessing these services. Many cancer surgeries and other treatments were postponed or delayed during the pandemic. 2 In Canada, both public health and cancer services are publicly funded and provincially managed. In March 2020, most provinces declared a state of public health emergency, which led to cancelation and postponement of many cancer treatments, screenings and routine healthcare visits. Provincial health agencies eventually issued directives and practice guidelines for cancer care provision during the pandemic. 7 Many included criteria for prioritization and triage of cancer patients in case of healthcare disruptions, and specified cancer treatments should be maintained as a high priority service. Cancer treatments gradually resumed over the next few months, 8 and our discussions with officials from cancer agencies indicated that most perceived cancer service provision had returned to normal over the course of 2020. However, fewer cancer treatments were performed in 2020, 8 suggesting many cancer cases experienced delays in their diagnosis and treatment due to the pandemic. Our objective was to predict the long-term impact of pandemicrelated cancer diagnostic and treatment delays on cancer mortality in Canada by cancer site, age, sex and province. We also examined factors which could mitigate or increase the expected cancer mortality over the next decade. We built an individual-level stochastic microsimulation model in C++. The model simulates the health trajectories of cancer cases over time and was designed to capture the impacts of diagnostic and treatment delays on cancer incidence and mortality ( Figure 1 ). The main model outcome was predicted excess cancer deaths caused by the pandemic, which were calculated as the difference in the number of cancer deaths between pandemic scenarios and a no pandemic The model's main features are described below; a more detailed description of parameters and assumptions can be found in Supporting information published elsewhere. 9 We modeled the incidence of 25 cancer sites (bladder, brain, breast, central nervous system, cervix, colorectal, esophagus, Hodgkin lymphoma, kidney and renal pelvis, larynx, leukemia, liver, lung, melanoma, multiple myeloma, non-Hodgkin lymphoma, oral, ovary, pancreas, prostate, stomach, testes, thyroid, uterus and all other cancers) based on 2015 to 2017 Canadian incidence rates 10 and population size by sex and age. 11 Cancers were assigned an overall TNM stage at diagnosis based on the distribution reported by provincial cancer registries. 12 Two death dates were sampled for each cancer case: their expected cancer death date and their expected death date from other causes. The expected cancer death date was sampled from a net cancer survival function depending on sex, age, cancer site and stage. [13] [14] [15] The expected death date from other causes was sampled from 2017 to 2019 Canadian life tables by sex, 16 adjusted for seasonality using a sinusoidal function fitted to weekly death counts. A cancer case's actual death date was the earliest of these two expected death dates. If the expected cancer death date was earlier than the expected death date from other causes, then we assumed that the person died from cancer. Four cancer treatment modalities were included in the model: surgery, radiotherapy, chemotherapy and other. Patients could receive combinations of surgery, radiotherapy and chemotherapy. Patients in the other category were those who did not receive any of these three treatments and received other care. We were unable to identify a nationally representative data set for the distribution of cancer treatments in Canada. We based treatment distributions on expert opinion from an Expert Advisory Group of 31 oncologists and surgeons, supplemented with data on treatment distributions from England and the United States. 17, 18 The experts used a survey tool to validate whether the treatment distributions from England and the United States were applicable to Canada based on their experience. If they judged treatment probabilities to differ, they were asked to quantify the probability of receiving each treatment for a given cancer site by stage. We combined the probability distributions elicited from experts using an equal weights linear opinion pool. 19 We defined the treatment interval as the time between the diagnosis date and the start date of curative or palliative treatment. The treatment interval was explicitly modeled: upon diagnosis, each cancer case was assigned a treatment interval sampled from a Weibull distribution, fitted to prepandemic reported times to cancer treatment. 6, 20 We defined the diagnostic interval as the time between the date a patient first notices cancer symptoms and the date of diagnosis. This definition included the patient interval 21 (time between noticing symptoms and presenting to healthcare) in the diagnostic interval, because declines in cancer diagnoses were due to patients both taking longer to present to healthcare as well as a reduction in diagnostic activities during the pandemic. This diagnostic interval was not explicitly modeled; however, the date of diagnosis could be delayed as described below, implicitly increasing the diagnostic interval. We modeled the pandemic's impact on healthcare delivery as a relative change in the monthly number of diagnoses and treatments compared to the numbers expected had there been no pandemic. This relative change set the maximum diagnostic and treatment capacity each month. Diagnoses and cancer treatments scheduled to occur which exceeded the monthly system capacity were placed on a backlog. During each time step, the model would attempt to clear the backlog by randomly selecting from the list of undiagnosed cases which were diagnosed, and selecting from the list of diagnosed untreated cases which received treatment, up to the maximum capacity. The backlogs increased during time steps where diagnostic and treatment volumes were below expected levels. Because selection of cases on the backlog was random, some cancer cases did not experience any delays, while other cases could experience significant diagnostic and treatment delays. There was a small À2.5% yearly percent change in the number of radiotherapies in Canada in 2020 compared to 2019 reported to CIHI. 6 We rescaled this percent change per month in the model so that the largest declines occurred in Spring, with recovery in the Summer and Fall. Changes in radiotherapies were only modeled for Québec, Ontario, New Brunswick and Prince Edward Island, as other provinces did not report declines in radiotherapies. 6 There was no data for chemotherapies; we assumed these would experience the same monthly percent changes as radiotherapies. We used 2019 to 2021 monthly pathology report data provided by the MSSS as a proxy for new diagnoses in Québec. This province reported a similar overall percent change in pathology reports as in cancer surgeries over 2020 to 2021. Based on this, we assumed for other provinces that the monthly decline in new diagnoses would be the same as the reported monthly decline in cancer surgeries ( Figure 2A ). The diagnostic delay was the difference between the date the cancer would have been diagnosed without the pandemic and the actual diagnosis date because of the diagnostic backlog. The treatment delay was the difference between the initially scheduled treatment date and the actual treatment date because of the treatment backlog. A metaanalysis estimated that each 4-week delay in cancer surgery leads to a 1.06 to 1.08 hazard ratio increase in mortality across several major cancer sites. 1 Hazard ratios for radiotherapy and systemic therapy delays were more variable, but included similar values in their confidence intervals. Based on this, we assumed that all cancer sites and all treatment modalities would have a 1.06 times higher cancer mortality hazard rate per 4-week treatment delay. We assumed the same hazard ratio would apply to a 4-week diagnostic delay. The relationship between time and mortality rates was assumed to be log-linear, with each 4-week delay increasing the mortality rate multiplicatively. The We also integrated a probability of a stage shift at diagnosis for breast, lung, colorectal and ovarian cancers due to diagnostic delays. 23 However, the probability of stage shifts was very small in the literature, leading to very few predicted stage shifts in the model. Because the risk of stage shifts is likely underestimated in the literature due to confounding by indication, 24 and consequently underestimated in the model, the diagnostic delay hazard ratio was the parameter largely used to account for pathways through which later diagnosis would lead to worse outcomes, including potential stage shifts. In the base case pandemic scenario, we assumed there would be declines in diagnoses and treatments from March 2020 to May 2021 ( Figure 2A ), and that, starting June 2021, treatment capacity would return to normal prepandemic levels and diagnostic capacity would increase by 15% due to increased diagnostic activities and increased patient interactions with the healthcare system. In sensitivity analyses, we evaluated more pessimistic scenarios, where treatment capacity remains 10% to 20% below prepandemic levels throughout 2021, and more optimistic scenarios, where treatment capacity is increased over normal capacity after June 2021 to decrease the treatment backlog. We also varied the mortality hazard ratio associated with a 4-week delay due to the high uncertainty regarding the effect of delays on cancer mortality. Simulations were run until the end of 2030; this cutoff date was determined based on the results of simulations, which showed that cancer mortality returned to expected levels by this date in all scenarios. Results are the median (minimum À maximum interval) of 10 stochastic simulations per scenario. The Columbia. In general, cancer sites with poor expected survival (pancreas, esophagus, lung) were predicted to experience lower relative mortality increases, though lung cancer accounted for many absolute excess deaths due to its high incidence. In sensitivity analyses, we varied the effect of delays on the mortality hazard ratio, stratified by site ( excess cancer deaths caused by the pandemic. This occurs for two reasons: (a) increasing treatment capacity helps clear treatment backlogs accumulated during the pandemic and (b) cancer treatment demand is predicted to increase in the future due to cancer diagnoses which were missed or delayed during the pandemic, but which are expected to eventually be diagnosed and require treatment. In the model, these delayed diagnoses are added to the treatment backlog and increase treatment wait times for all cancers once diagnosed, unless treatment capacity is increased to meet demand. While we did not assess the duration of time that would be necessary to maintain increased treatment capacity to reduce cancer mortality, it is likely that the period of increased needs will span the period of time required to diagnose and treat the cancers which were missed during 2020 to 2021. Our results in Figure 3 suggest the period of increased treatment needs could span until at least the end of 2022. This is consistent with another study which estimated that it could take between 46 and 145 weeks to clear the accumulated pandemic surgical backlog assuming a +10% surge capacity in Ontario, Canada. 25 Some provincial governments have announced investments to address diagnostic and treatment backlogs, but it is unclear whether these will be sufficient to prevent excess cancer mortality. Some provinces also experienced their worst COVID-19 pandemic wave in the Fall of 2021, potentially leading to further decreases in healthcare capacity. Ongoing healthcare worker staffing shortages across Canada may also limit increases in diagnostic and treatment capacity. Much evidence suggests an important part of the observed decline in cancer treatments is likely attributable to cancer diagnostic delays, and not necessarily treatment delays. Cancer surgical wait-times returned to normal and even improved in Canada during 2020; however, the cumulative number of surgeries was lower than in previous years. 5, 6 Fewer pathology reports, MRI scans and CT scans have been performed than in previous years. 5, 6 Many diagnostic procedures and cancer screenings such as colonoscopies and mammographies were interrupted or slowed due to the pandemic. 5, 26 This suggests there is a backlog of undiagnosed cancers that have yet to be identified for treatment, either due to decreased patient interactions with the healthcare system or due to delays in the diagnostic pathway. An important part of the modelpredicted excess mortality is attributable to these delayed diagnoses which will eventually require treatment. These delayed diagnoses may not yet be apparent in observed treatment backlogs and waitlists, but should be accounted for in the planning for future healthcare needs, especially as many are likely to present with more advanced cancers. Diagnostic and treatment delays are hypothesized to lead to worse cancer survival due to tumor progression, leading to later stage at diagnosis and treatment. We were unable to predict the impact of delays on stage shifts in the model due to a lack of quality data on the quantitative relationship between time and the risk of stage progression. Much of the literature on this topic is biased by a wait time paradox, a type of confounding by indication where cancers with worse survival have shorter diagnostic and treatment intervals due to being prioritized in cancer care pathways. 23, 24, 27 However, there is concern that early stage cancers which went undiagnosed during the pandemic may eventually present at later stages. 28 Later stages at diagnosis with worse survival are expected to account for part of the future cancer mortality increase. As evidence on this topic accrues, we plan to further integrate the probability of stage shifts in the model when better data becomes available. An important limitation of our model is that we were not able to integrate triaging of cases and treatment substitutions during the pandemic. Many provinces implemented clinical protocols to prioritize the treatment of the most severe cancer cases and to provide alternative treatments in order to minimize the impact of treatment delays. 7 Given the paucity of detailed data on how these policies were implemented on the ground, it was not possible to model the impact of these policies. The causal effect of cancer care trajectory delays on cancer mortality is the most uncertain parameter in our model. Research on this topic has been challenging due to the wait time paradox. 27 We based the effect of delays in the model on results from a high-quality systematic review that accounted for the wait time paradox. 1 The effects of delays in our model were similar to those assumed by other models. British Columbia 2832 (2392; 3994) Manitoba 957 (662; 1185) Site Bladder Cervix 267 (132; 469) Colorectal 4305 (3789; 4676) Hodgkin lymphoma 129 (73; 218) Kidney and renal pelvis 608 (470; 784) Non-Hodgkin lymphoma 1566 (1438; 1839) Testis 66 (10; 120) Mortality due to cancer treatment delay: systematic review and meta-analysis The impact of the COVID-19 pandemic on cancer care Anticipated help-seeking for cancer symptoms before and after the coronavirus pandemic: results from the Onco-barometer population survey in Spain Gjini Ardiana & Brain Kate et al. The impact of COVID-19 on cancer symptom experience and help-seeking behaviour in the United Kingdom: a cross-sectional population survey Analyse des répercussions de la pandémie de la COVID-19 sur les soins et services en cancérologie au Québec Wait times for priority procedures in Canada -data table McGill Task Force on Covid-and Cancer. A review of Canadian cancer-related clinical practice guidelines and resources during the COVID-19 pandemic COVID-19's effect on hospital care services Malag on T. Model technical documentation. 2021. Publisher, V1 Number and rates of new cases of primary cancer, by cancer type, age group and sex Population estimates on July 1st, by age and sex Canadian Cancer Society's Advisory Committee on Cancer Statistics Canadian Cancer Statistics: a 2018 special report on cancer incidence by stage in Canada Canadian Cancer Society's Advisory Committee on Cancer Statistics Progress in net cancer survival in Canada over 20 years Pop Est Summary (Statistics Canada, Ontario Ministry of Finance Life tables, Canada, provinces and territories. Catalogue no Cancer Research UK. Chemotherapy, radiotherapy and surgical tumour resections in England Cancer Treatment & Survivorship Facts & Figures Combining probability distributions from experts in risk analysis The Aarhus statement: improving design and reporting of studies on early cancer diagnosis Evolution de la COVID-19 Advanced-stage cancer and time to diagnosis: an International Cancer Benchmarking Partnership (ICBP) cross-sectional study Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review Clearing the surgical backlog caused by COVID-19 in Ontario: a time series modelling study Measuring the impact of the COVID-19 pandemic on organized cancer screening and diagnostic follow-up care in Ontario, Canada: a provincial, population-based study The waiting time paradox: population based retrospective study of treatment delay and survival of women with endometrial cancer in Scotland Covid-19: early stage cancer diagnoses fell by third in first lockdown Integrated survival estimates for cancer treatment delay among adults with cancer during the COVID-19 pandemic Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study Impact of the COVID-19 pandemic on breast cancer mortality in the US: estimates from collaborative simulation modeling The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: a modelled analysis The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada McGill Task Force on the Impact of COVID-19 on Cancer Control and Care. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada Shinder; (Members Serving an Advisory Role) Armen Aprikian